Avastin News and Research

RSS
Avastin is a biologic antibody designed to specifically bind to a protein called vascular endothelial growth factor (VEGF) that plays an important role throughout the lifecycle of the tumor to develop and maintain blood vessels, a process known as angiogenesis. Avastin is designed to interfere with the blood supply to a tumor by directly binding to the VEGF protein to prevent interactions with receptors on blood vessel cells. Avastin does not bind to receptors on normal or cancer cells. The tumor blood supply is thought to be critical to a tumor’s ability to grow and spread in the body (metastasize).
Allergan, Amgen submit BLA for ABP 215 oncology biosimilar medicine to FDA

Allergan, Amgen submit BLA for ABP 215 oncology biosimilar medicine to FDA

Scottish women with metastatic carcinoma of cervix could now benefit from Avastin treatment

Scottish women with metastatic carcinoma of cervix could now benefit from Avastin treatment

NEI-funded study analyzes outcomes of anti-VEGF therapy for AMD

NEI-funded study analyzes outcomes of anti-VEGF therapy for AMD

Research unveils standard front-line treatment for advanced ovarian cancer

Research unveils standard front-line treatment for advanced ovarian cancer

Bevacizumab extends survival of pleural mesothelioma patients

Bevacizumab extends survival of pleural mesothelioma patients

New campaign raises awareness of City of Hope's life-saving mission and impact

New campaign raises awareness of City of Hope's life-saving mission and impact

NAM announces election of three new members from UC San Diego School of Medicine

NAM announces election of three new members from UC San Diego School of Medicine

Specific biomarker predicts which HER2-negative breast cancer patients respond to targeted therapy

Specific biomarker predicts which HER2-negative breast cancer patients respond to targeted therapy

DelMar presents updated VAL-083 Phase I/II trial data at GBM2015 meeting

DelMar presents updated VAL-083 Phase I/II trial data at GBM2015 meeting

Risk for endophthalmitis no higher with Avastin, finds study

Risk for endophthalmitis no higher with Avastin, finds study

UCLA's Jonsson Comprehensive Cancer Center named among top 10 cancer centers in nation

UCLA's Jonsson Comprehensive Cancer Center named among top 10 cancer centers in nation

Low BMI linked to poorer survival in advanced colorectal cancer

Low BMI linked to poorer survival in advanced colorectal cancer

Study may predict which glioblastoma patients may respond well to dasatinib drug treatment

Study may predict which glioblastoma patients may respond well to dasatinib drug treatment

Value of Colorectal Cancer therapeutics market expected to increase $9.4 billion by 2020

Value of Colorectal Cancer therapeutics market expected to increase $9.4 billion by 2020

Celldex’s lead program RINTEGA demonstrates overall survival benefit in patients with recurrent glioblastoma

Celldex’s lead program RINTEGA demonstrates overall survival benefit in patients with recurrent glioblastoma

Medicare physician reimbursement data could be confusing to the public

Medicare physician reimbursement data could be confusing to the public

VBL Therapeutics reports positive results from VB-111 Phase 1/2a study in recurrent platinum-resistant Müllerian cancer

VBL Therapeutics reports positive results from VB-111 Phase 1/2a study in recurrent platinum-resistant Müllerian cancer

Additional preclinical data on DelMar’s VAL-083 to treat temozolomide-resistant GBM presented at AACR

Additional preclinical data on DelMar’s VAL-083 to treat temozolomide-resistant GBM presented at AACR

DelMar to present new data on development of VAL-083 at 2015 ASCO Annual Meeting

DelMar to present new data on development of VAL-083 at 2015 ASCO Annual Meeting

First new treatment authorised in a decade for advanced cervical cancer patients in the UK

First new treatment authorised in a decade for advanced cervical cancer patients in the UK